Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Lelisa Gemta"'
Autor:
James DeGregori, Douglas K. Graham, Natalie J. Serkova, Craig T. Jordan, Daniel A. Pollyea, Michael F. Wempe, Vijay Kumar, Amit Kumar, Lelisa Gemta, Amanda A. Hill, Vadym Zaberezhnyy, Brett M. Stevens, Deborah DeRyckere, Catherine Pham-Danis, Mark A. Gregory, Francesca Alvarez-Calderon
Supplemental Tables 1-4. Table 1: pLKO shRNA clone information and antibody information. Table 2: Combination Indices to assess for synergism. Table 3: Quantitative 1H-, 31P- and 13C-NMR analysis of K562 CML cells treated with vehicle imatinib, oligo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296e16a4b6875e8ab0dd71b2335091f2
https://doi.org/10.1158/1078-0432.22458098
https://doi.org/10.1158/1078-0432.22458098
Autor:
James DeGregori, Douglas K. Graham, Natalie J. Serkova, Craig T. Jordan, Daniel A. Pollyea, Michael F. Wempe, Vijay Kumar, Amit Kumar, Lelisa Gemta, Amanda A. Hill, Vadym Zaberezhnyy, Brett M. Stevens, Deborah DeRyckere, Catherine Pham-Danis, Mark A. Gregory, Francesca Alvarez-Calderon
Supplemental Figures 1-8. Figure 1. Mitochondrial metabolism becomes essential for TKI-treated BCR-ABL+ leukemia cells. Figure 2: Oligomycin-A sensitizes cells to BCR-ABL inhibition. Figure 3. Oligomycin-A sensitizes cells to BCR-ABL inhibition. Figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985e6043e742f651180c52f3e1542f97
https://doi.org/10.1158/1078-0432.22458104
https://doi.org/10.1158/1078-0432.22458104
Autor:
James DeGregori, Douglas K. Graham, Natalie J. Serkova, Craig T. Jordan, Daniel A. Pollyea, Michael F. Wempe, Vijay Kumar, Amit Kumar, Lelisa Gemta, Amanda A. Hill, Vadym Zaberezhnyy, Brett M. Stevens, Deborah DeRyckere, Catherine Pham-Danis, Mark A. Gregory, Francesca Alvarez-Calderon
Supplemental Methods. This supplementary file includes additional methods for sample preparation, Seahorse analysis of oxygen consumption rates, reactive oxygen species measurements, flow cytometry analysis, NMR analysis, RT-PCR conditions, quizartin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c16e24b7f7169c7b082b382b70e632a
https://doi.org/10.1158/1078-0432.22458101
https://doi.org/10.1158/1078-0432.22458101
Autor:
James DeGregori, Douglas K. Graham, Natalie J. Serkova, Craig T. Jordan, Daniel A. Pollyea, Michael F. Wempe, Vijay Kumar, Amit Kumar, Lelisa Gemta, Amanda A. Hill, Vadym Zaberezhnyy, Brett M. Stevens, Deborah DeRyckere, Catherine Pham-Danis, Mark A. Gregory, Francesca Alvarez-Calderon
Purpose: Although tyrosine kinase inhibitors (TKI) can be effective therapies for leukemia, they fail to fully eliminate leukemic cells and achieve durable remissions for many patients with advanced BCR-ABL+ leukemias or acute myelogenous leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c7963b92542137c227ee116e3c36d83
https://doi.org/10.1158/1078-0432.c.6523826.v1
https://doi.org/10.1158/1078-0432.c.6523826.v1
Autor:
Charles Spivey, Scott M. Seki, Alban Gaultier, Vlad Serbulea, Anthony Fernandez-Castaneda, Nikolas William Hayes, Rebecca L. McCloud, Ku-Lung Hsu, Lelisa Gemta, Dorian A. Rosen, Sarah C. Nanziri, Kacper Posyniak, Timothy N. J. Bullock, Rebecca M. Beiter
Publikováno v:
Sci Signal
Immunometabolism
Immunometabolism
Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell function, we assessed their therapeutic activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8aee33d056a8440d07dfdc277416f4
https://doi.org/10.1126/scisignal.aay9217
https://doi.org/10.1126/scisignal.aay9217
Autor:
Scott M. Seki, Timothy N. J. Bullock, Max Stevenson, Abagail M. Rosen, Alban Gaultier, Lelisa Gemta, Sanja Arandjelovic
Publikováno v:
The Journal of Immunology. 198:4607-4617
Multiple sclerosis (MS) is a disease that is characterized by immune-mediated destruction of CNS myelin. Current MS therapies aim to block peripheral immune cells from entering the CNS. Although these treatments limit new inflammatory activity in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42bb47da51fb03e37f22731c6647c70c
https://doi.org/10.4049/jimmunol.1600825
https://doi.org/10.4049/jimmunol.1600825
Autor:
Ku-Lung Hsu, Kacper Posyniak, Timothy N. J. Bullock, Charles Spivey, Rebecca M. Beiter, Scott M. Seki, Rebecca L. McCloud, Nikolas William Hayes, Lelisa Gemta, Dorian A. Rosen, Alban Gaultier, Anthony Fernandez-Castaneda
Publikováno v:
SSRN Electronic Journal.
T cells play crucial, and perhaps initiating roles in autoimmune diseases like Multiple Sclerosis (MS). Elucidating the mechanisms that regulate inflammatory T cell responses could reveal novel means of modulation of their pathological role. Small mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1952bb5d6157a45296fb1b1082877e6
https://doi.org/10.2139/ssrn.3363732
https://doi.org/10.2139/ssrn.3363732
Autor:
Francesca Alvarez-Calderon, Daniel A. Pollyea, Amanda A. Hill, Natalie J. Serkova, Vijay Kumar, Lelisa Gemta, Amit Kumar, Catherine Pham-Danis, Vadym Zaberezhnyy, Douglas K. Graham, Craig T. Jordan, Mark A. Gregory, Deborah DeRyckere, Michael F. Wempe, James DeGregori, Brett M. Stevens
Publikováno v:
Clinical Cancer Research. 21:1360-1372
Purpose: Although tyrosine kinase inhibitors (TKI) can be effective therapies for leukemia, they fail to fully eliminate leukemic cells and achieve durable remissions for many patients with advanced BCR-ABL+ leukemias or acute myelogenous leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9007f056946e0d509a2a7547031988e
https://doi.org/10.1158/1078-0432.ccr-14-2146
https://doi.org/10.1158/1078-0432.ccr-14-2146
Autor:
Timothy N. J. Bullock, Kyle L. Hoehn, Peter J. Siska, Craig L. Slingluff, Jeffrey C. Rathmell, Xiaojing Liu, Jason W. Locasale, Hideo Yagita, Xia Gao, Marin E. Nelson, Lelisa Gemta
Publikováno v:
Science immunology. 4(31)
In the context of solid tumors, there is a positive correlation between the accumulation of cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and favorable clinical outcomes. However, CD8+ TILs often exhibit a state of functional exhaustion, limit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ce1f8431dcd9914ef9ce3b911436f0e
https://pubmed.ncbi.nlm.nih.gov/30683669
https://pubmed.ncbi.nlm.nih.gov/30683669
Autor:
Kathryn E. Beckermann, Timothy N. J. Bullock, Gabriela Andrejeva, Chiu Lan Chen, Peter J. Siska, W. Kimryn Rathmell, Adam B. Sendor, Allison R. Greenplate, Jonathan M. Irish, Jeffrey C. Rathmell, Yun Chen J. Chiang, Bumki Kim, Benjamin G. Vincent, Lelisa Gemta, Frank M. Mason, Jiyong Hong, Armando L. Corona, Richard C. Wang
Publikováno v:
JCI Insight. 2
Cancer cells can inhibit effector T cells (Teff) through both immunomodulatory receptors and the impact of cancer metabolism on the tumor microenvironment. Indeed, Teff require high rates of glucose metabolism, and consumption of essential nutrients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5602571f13fbca037f9da5edbcbde08
https://doi.org/10.1172/jci.insight.93411
https://doi.org/10.1172/jci.insight.93411